Literature DB >> 25992150

Is primary hyperparathyroidism a risk factor for papillary thyroid cancer? An exemplar study and literature review.

Udi Cinamon1, Dalia Levy1, Tal Marom1.   

Abstract

Introduction Primary hyperparathyroidism (PHPT) is associated with several cancer types, including papillary thyroid carcinoma (PTC). Objective To explore further the relation between PHPT and PTC. Methods By considering patients with PHPT as extra-suspicious for PTC, we studied an exemplar group of patients with PHPT with a small (≤1 cm) thyroid nodule, which was negative in preoperative cytologic examination. During parathyroidectomy, a frozen section biopsy of the thyroid nodule confirmed PTC, as did the final surgical specimen, revealing that the preoperative cytology was false-negative. Additionally, relevant reports retrieved from the English literature addressing thyroid cancer and hyperparathyroidism were reviewed and processed. Results Four patients with PHPT were studied. Three had a multifocal thyroid disease, and three had neck lymph node metastasis. Processing previous report data supported an association between PHPT and PTC. Although thyroid nodularity among patients with PHPT was similar to the general population, PTC incidence was higher. This was true also for patients with secondary hyperparathyroidism. Conclusions This study emphasized that PHPT should be considered as a noteworthy risk factor for PTC. Fine needle aspiration of a thyroid nodule is the most valuable diagnostic procedure for thyroid cancer. Yet, false-negative results were reported in up to 10% of cases, especially in small, subcentimeter nodules. In line with our data and the literature, patients with PHPT should have both a detailed ultrasound addressing the thyroid and cytology of any thyroid nodule, including small subcentimeter lesions. Moreover, surgical flexibility, allowing intraoperative thyroid nodule sampling, should be considered even for "innocent" nodules.

Entities:  

Keywords:  hyperparathyroidism; parathyroid adenoma; parathyroidectomy; thyroid cancer; thyroid nodule

Year:  2014        PMID: 25992150      PMCID: PMC4392524          DOI: 10.1055/s-0034-1396520

Source DB:  PubMed          Journal:  Int Arch Otorhinolaryngol        ISSN: 1809-4864


Introduction

The coexistence of thyroid nodule and primary hyperparathyroidism (PHPT) presents a clinical diagnostic and management challenges. Previous investigations have reported a relatively high, but versatile, incidence of 12 to 52% of thyroid nodules in patients with PHPT1 2 3 and 5 to 26% among patients with PHPT with thyroid disease requiring surgery.3 Frequent thyroid nodules have also been detected by ultrasound (US) in patients with secondary hyperparathyroidism (SHPT).4 Other observations have indicated an increased risk for cancer in patients with PHPT, mainly of hematopoietic, breast, and urinary tract malignancies, but also endocrine neoplasms.5 6 With the exception of familial endocrinopathies, the association between hyperparathyroidism and thyroid cancer has neither frequently reported nor widely discussed. Therefore, the clinical significance of concomitant thyroid cancer and hyperparathyroidism remains unclear. The objective of this study was to explore the presumed association between PHPT, thyroid nodularity, and thyroid cancer by conducting an exemplar case series study, specifically addressing small (≤1 cm), otherwise “innocent,” nonsuspicious thyroid nodules (by preoperative US and cytology) copresenting in patients with PHPT scheduled for parathyroidectomy that intra- and postoperative surgical pathology revealed as papillary thyroid carcinoma (PTC). Additionally, relevant observations retrieved from the English literature addressing thyroid cancer and hyperparathyroidism (both PHPT and SHPT) were reviewed, processed, and presented.

Methods

This work has been approved by the local Institutional Review Board. An exemplar group of patients diagnosed with PHPT was studied. All had both a preoperative 99m Tc-MIBI (methoxyisobutyl isonitrile) scan and neck US suggesting a single parathyroid adenoma and were scheduled for an elective parathyroidectomy. In addition, all preoperative US studies demonstrated a small, benign-appearing thyroid nodule. US-guided fine needle aspiration (FNA) results from these thyroid nodules were also reported to be benign (II, according the Bethesda system for reporting thyroid cytopathology).7 All the patients were otherwise healthy, and none had any risk factors related to thyroid cancer according to the American Thyroid Association (ATA) 2009 guidelines (i.e., prior thyroid cancer, family history, or exposure to external irradiation).8 All patients underwent surgery in which a parathyroid adenoma was excised. By addressing these patients with PHPT as extra-suspicious for PTC, the thyroid lesion was sent for an intraoperative frozen section pathologic examination, which confirmed PTC. Thus, as planned and discussed before surgery, with consent given, total thyroidectomy was performed in addition to the parathyroidectomy.

Results

The preoperative workup and intraoperative courses of the four patients are summarized in Table 1 and Table 2, respectively. The postoperative recovery and follow-up were uneventful in all patients; postoperative parathyroid hormone and calcium blood levels returned to normal values. Surgical pathology of all the thyroid lesions was reported as PTC, classical variant, without evidence for an extracapsular spread (Table 2). Patient 3 had an uneventful completion thyroidectomy 2 weeks after the first surgery, whereas patient 4 decided not to have completion thyroidectomy. Patients 1, 2, and 3 were later referred for ablative iodine 131 treatment.
Table 1

Preoperative workup in four patients with primary hyperparathyroidism

CharacteristicsPatient
1234
Age (y)32553949
GenderMaleFemaleFemaleFemale
Preoperative PTH levela 75120120121
Preoperative calcium levelb 1111.211.211
Parathyroid adenoma localizing studiesc Adjacent to the right thyroid lobe, lower poleLateral and deep to the right thyroid lobeNear the inferior pole of the right thyroid lobeDeep and posterior to the right thyroid lobe
Other neck ultrasound findings10 × 7-mm, right thyroid lobe hypoechogenic nodule, with regular borders, without calcifications, no lymphadenopathy5-mm nodule with fine calcifications in the right thyroid lobe and 3 smaller foci (<2 mm) in the left thyroid lobe7.5 × 5-mm hypoechoic nodule with regular borders in the right thyroid lobe, no lymphadenopathy9-mm nodule in the left thyroid lobe, with some fine calcifications, no lymphadenopathy
Preoperative thyroid FNA reportBenign-appearing follicular cellsColloid and benign-appearing follicular cellsA few benign follicular cells and some red blood cellsFollicular cells and colloid

Abbreviations: FNA, fine needle aspiration; PTH, parathyroid hormone.

Normal PTH level range: 10–65 pg/mL.

Normal serum calcium range: 8.5–10.3 mg/dL.

99m Tc-MIBI scan and neck ultrasound study.

Table 2

Intraoperative course of four patients with PHPT

Patient
1234
Operative findings in the thyroid fieldFirm nodule in the right thyroid gland upon palpationFirm nodule in the right thyroid gland upon palpation, ill-looking ipsilateral lymph nodes in levels III, IVFirm nodule in the right thyroid gland upon palpationFirm nodule in the right thyroid gland upon palpation
Frozen section reportPTCPTCSuspected PTCSuspected PTC
Surgeon's decisionTotal thyroidectomy + level VI neck dissectionTotal thyroidectomy + level VI neck dissection+ right levels III, IV selective neck dissectionHold thyroidectomy; wait for final pathological resultRight hemithyroidectomy; wait for final pathologic result

Abbreviation: PTC, papillary thyroid carcinoma.

Abbreviations: FNA, fine needle aspiration; PTH, parathyroid hormone. Normal PTH level range: 10–65 pg/mL. Normal serum calcium range: 8.5–10.3 mg/dL. 99m Tc-MIBI scan and neck ultrasound study. Abbreviation: PTC, papillary thyroid carcinoma. The MEDLINE electronic database was searched to identify relevant studies. For this purpose, we used the following free-text terms: “hyperparathyroidism” with “thyroid cancer” or “risk factor” or “hypercalcemia,” and limited to “human.” In addition, relevant studies were also extensively searched for by hand. Time and language limitations were applied to the years 1900 to 2014 and English, respectively. Data regarding the occurrence of thyroid nodules among patients with PHPT were reported to match the general population.9 10 However, processing reported information regarding PTC among patients with PHPT who were operated for parathyroid adenoma suggested a 5% incidence rate of coexistence of thyroid cancer and PHPT.1 2 9 10 11 12 13 14 15 The range varies between 3.3 and 15% (Table 3).
Table 3

Papillary thyroid cancer among patients with PHPT undergoing parathyroidectomy

AuthorNo. of PHPT patientsNo. of patients with thyroid cancer%
Attie and Vardhan2 948313.3
Cinamon and Turcotte11 582254.3
Strichartz and Giuliano12 308113.5
Morita et al1 200126
Rivo Vázquez et al13 12464.8
Masatsugu et al9 1091917.4
Arciero et al14 9466.4
Ogawa et al10 85910
Gul et al15 60915
Total2,5101285

Abbreviation: PHPT, primary hyperparathyroidism.

Abbreviation: PHPT, primary hyperparathyroidism.

Discussion

This study questioned whether patients with PHPT have a higher risk for PTC in comparison with the general population. All the same, to date the ATA guidelines do not consider PHPT a risk factor for thyroid cancer. An increased awareness and earlier diagnosis of PHPT has been partially attributed to the popular routine automated biochemical testing, in addition to targeting middle-aged women with blood calcium screening in an aging society.16 Furthermore, other reports suggested that patients with PHPT may have an elevated risk to encounter cancer including thyroid cancer.5 6 Concurrently, thyroid cancer incidence has been reported to increase worldwide. The reasons are not clear, yet an increased US detection rate of thyroid lesions is probably only a partial explanation.17 18 19 20 21 When based on physical examination alone, the incidence of thyroid nodularity was estimated to be 6.4% among female subjects and 1.5% in male subjects, and the incidence of thyroid nodules was 37 to 57% in autopsies series, with similar figures when detected by US.22 Contemporarily, FNA is the most valuable diagnostic procedure for PTC; however, false-negative results may be as high as 10%, especially in small, subcentimeter nodules.23 24 25 This issue has been addressed by the revised ATA management guidelines for patients with thyroid nodules and differentiated thyroid cancer. These recommendations concluded that “routine FNA is not recommended for sub-centimeter nodules . . . patients for whom consideration of FNA of a sub-centimeter nodule may be warranted include those with a higher likelihood of malignancy (high risk history), i.e., family history of PTC, history of external beam radiation exposure as a child, exposure to ionizing radiation in childhood or adolescence, history of prior hemithyroidectomy with discovery of thyroid cancer, and 18FDG-PET [fluorine-18 fluorodeoxyglucose positron emission tomography]-positive thyroid nodules.”8 Regarding “size,” the current study presented four patients with PHPT, without any ATA-recognized risk factors for thyroid cancer, who presented with a small, unsuspicious thyroid nodule, which would not have been studied otherwise but nevertheless proved to harbor PTC in the postoperative pathologic examination. Roti et al reported that tumors ≤10 mm accounted for 39% of all thyroid cancers, and local lymph node invasion occurred in 0.8% of tumors < 5 mm and in 1.6 to 3.3% of patients with nodules 6 to 10 mm in size.26 Recent worldwide data reported the incidence of thyroid cancer to be ∼2 to 12 per 100,000 per year new cases, and the estimated lifetime risk for developing thyroid among the general population was reported to be 1:842 for men and 1:324 for women (in the United Kingdom).17 18 19 20 21 Our original assessment of previously reported data suggested a high (5%) rate of thyroid cancer among patients with PHPT undergoing parathyroidectomy (ranging 3.3 to 15%, 128 thyroid carcinoma cases among 2,510 patients with PHPT; Table 3).1 2 9 10 11 12 13 14 15 Although expressed in incomparable statistical measures, this rate suggests significance. Noteworthy are reports associating SHPT and thyroid cancer, thus contributing an additional argument that hyperparathyroidism may indeed predispose for thyroid cancer.27 28 29 Finally, a nontraditional operative approach (i.e., obtaining an intraoperative biopsy of a small thyroid nodule with a benign preoperative cytology) in a high-risk patient (with PHPT) has been shown to be rewarding. It is important to note that the intraoperative examinations of the thyroid nodules have been proven to be reliable, as described in the same context.30

Conclusion

Larger population studies are required to determine if hyperparathyroidism is a significant risk factor for PTC. At this time, we suggest that patients with PHPT should be regarded as extra-suspicious for PTC. Therefore, a comprehensive preoperative thyroid workup, including FNA, should be performed in all patients with PHPT, even for small thyroid nodules (≤1 cm). Despite an otherwise innocent preoperative evaluation of a thyroid nodule in patients with PHPT, flexible surgical planning with optional intraoperative thyroid tissue sampling should be considered during surgery.
  28 in total

1.  Appropriate and accurate diagnosis of thyroid nodules: a review of thyroid fine-needle aspiration.

Authors:  Catherine Hambleton; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2013-06-26

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Significant clinical differences in primary hyperparathyroidism between patients with and those without concomitant thyroid disease.

Authors:  Toshihiro Masatsugu; Hiroyuki Yamashita; Shiro Noguchi; Ryuichi Nishii; Shin Watanabe; Shinya Uchino; Syoji Kuroki; Masao Tanaka
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Preoperative and postoperative evaluation of thyroid disease in patients undergoing surgical treatment of primary hyperparathyroidism.

Authors:  Kamile Gul; Didem Ozdemir; Birol Korukluoglu; Pamir Eren Ersoy; Raci Aydin; Serdar Nevzat Ugras; Reyhan Ersoy; Bekir Cakir
Journal:  Endocr Pract       Date:  2010 Jan-Feb       Impact factor: 3.443

6.  Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

Authors:  P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

7.  Ultrasonographic detection of thyroid nodules in hemodialysis patients in Japan.

Authors:  Toru Sanai; Ken Okamura; Teruo Inoue; Tetsuya Abe; Kazuhiko Tsuruya; Koichi Node
Journal:  Ther Apher Dial       Date:  2010-06       Impact factor: 1.762

8.  [Hyperparathyroidism, goiter and well-differentiated thyroid carcinoma. A common association with diagnostic implications].

Authors:  Angel Rivo Vázquez; José Eduardo Rivo Vázquez; Nieves Cáceres Alvarado; Reyes Meléndez Villar; Concepción Páramo Fernández; Hipólito Piñeiro Martínez; Pedro Gil Gil
Journal:  Cir Esp       Date:  2007-07       Impact factor: 1.653

9.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.

Authors:  Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more
  8 in total

1.  Does Primary Hyperparathyroidism Have an Association with Thyroid Papillary Cancer? A Retrospective Cohort Study.

Authors:  Kenan Çetin; Hasan E Sıkar; Şule Temizkan; Cem B Ofluoğlu; Ayşenur Özderya; Kadriye Aydın; Aylin E Gül; Hasan F Küçük
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

2.  ARE THYROID NODULES AN OBSTACLE TO MINIMAL INVASIVE PARATHYROID SURGERY? A SINGLE-CENTER STUDY FROM AN ENDEMIC GOITER REGION.

Authors:  S Özden; B Saylam; G Daglar; Y N Yuksek; M Tez
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

3.  Symptomatic Primary Hyperparathyroidism as a Risk Factor for Differentiated Thyroid Cancer.

Authors:  Guadalupe Vargas-Ortega; Lourdes Balcázar-Hernández; Baldomero González-Virla; Claudia Ramírez-Rentería; Oriana Nieto-Guzmán; Ana Pamela Garrido-Mendoza; Marco Antonio Flores-Maya; Moisés Mercado; Mendoza-Zubieta Victoria
Journal:  J Thyroid Res       Date:  2018-11-18

4.  Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study.

Authors:  Chaiho Jeong; Hye In Kwon; Hansang Baek; Hun-Sung Kim; Dong-Jun Lim; Ki-Hyun Baek; Jeonghoon Ha; Moo Il Kang
Journal:  Endocrinol Metab (Seoul)       Date:  2020-12-10

5.  Primary Hyperparathyroidism with Thyroid Cancer: Clinicopathologic Features.

Authors:  Selda Gucek Haciyanli; Serkan Karaisli; Beste Suataman; Furkan Karahan; Mehmet Haciyanli
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2022-06-28

6.  Brown tumor mimicking metastases-the late manifestation of hyperparathyroidism.

Authors:  Louise Tram; Magdalena Kubik; Kristina Kvist Jensen; Charlotte E Almasi
Journal:  Acta Radiol Open       Date:  2022-09-17

7.  The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement.

Authors:  Bambang Udji Djoko Rianto; Anton Sony Wibowo; Camelia Herdini
Journal:  Int Arch Otorhinolaryngol       Date:  2019-11-04

8.  Increased thyroid malignancy in patients with primary hyperparathyroidism.

Authors:  Luchuan Li; Baoyuan Li; Bin Lv; Weili Liang; Binbin Zhang; Qingdong Zeng; Andrew G Turner; Lei Sheng
Journal:  Endocr Connect       Date:  2021-08-02       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.